Myriad and Pfizer Signs a Service Agreement for Testing of BRCA-Mutated Triple Negative Breast Cancer

 Myriad and Pfizer Signs a Service Agreement for Testing of BRCA-Mutated Triple Negative Breast Cancer

Myriad and Pfizer Signs a Service Agreement for Testing of BRCA-Mutated Triple Negative Breast Cancer

Shots:

  • Myriad to provide BRACAnalysis CDx testing device in P-II study conducted to evaluate Pfizer’s talazoparib for neo-adjuvant treatment of germline BRCA-mutated triple negative breast cancer
  • BRACAnalysis CDx is an IVD device used for qualitative detection and classification of protein coding regions & intron/exon boundaries of BRCA1 and BRCA2 gene
  • In April, 2015 Myriad and AstraZeneca also entered into agreement for evaluating Lynparza in patients with metastatic pancreatic cancer using Myriad’s BRACAnalysis CDx test

Click here to read full press release/ article | Ref: Myriad | Image: Forbes

Shiwani Sharma

Shiwani Sharma was Senior Editor at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post